BACKGROUND: Several studies have employed immunohistochemistry to detect Her2/neu overexpression in urothelial carcinomas, yielding a tremendous range of positive expression rates. Few studies have examined Her2 status in non-muscle invasive bladder cancer (NMIBC) using fluorescence in situ hybridisation (FISH). AIM: To evaluate Her2 amplification in NMIBC (Ta/T1), to correlate the findings with recurrence and progression, and compare the Her2 status between primary and progressive tumours. METHODS: FISH and immunohistochemistry for Her2/neu were performed on tissue arrays consisting of 36 papillary urothelial neoplasms of low malignant potential (PUNLMPs), 190 low grade urothelial carcinomas (LG-UCs) and 178 high grade urothelial carcinomas (HG-UCs). 32 cases with specimens of both primary and progressive tumours (from Ta/T1 to T2-4) were included for comparative analyses. RESULTS: 16 HG-UCs (9.0%) showed Her2 gene amplification while none of the PUNLMPs and LG-UCs showed this aberration. There was 100% concordance in the status of Her2 amplification between primary and progressive lesions. Immunohistochemistry and FISH results were in closest agreement when overexpression was defined as 50% of tumour cells showing immunoreactivity. The cumulative incidences of recurrence and progression in Her2-amplified HG-UC were significantly higher than in those without amplification. CONCLUSIONS: A subset of high-grade NMIBCs contain Her2 amplification and are associated with markedly aggressive behaviour. Her2 diagnostics are valuable for distinguishing patients who require diligent surveillance and would potentially benefit from anti-Her2 therapies.
BACKGROUND: Several studies have employed immunohistochemistry to detect Her2/neu overexpression in urothelial carcinomas, yielding a tremendous range of positive expression rates. Few studies have examined Her2 status in non-muscle invasive bladder cancer (NMIBC) using fluorescence in situ hybridisation (FISH). AIM: To evaluate Her2 amplification in NMIBC (Ta/T1), to correlate the findings with recurrence and progression, and compare the Her2 status between primary and progressive tumours. METHODS: FISH and immunohistochemistry for Her2/neu were performed on tissue arrays consisting of 36 papillary urothelial neoplasms of low malignant potential (PUNLMPs), 190 low grade urothelial carcinomas (LG-UCs) and 178 high grade urothelial carcinomas (HG-UCs). 32 cases with specimens of both primary and progressive tumours (from Ta/T1 to T2-4) were included for comparative analyses. RESULTS: 16 HG-UCs (9.0%) showed Her2 gene amplification while none of the PUNLMPs and LG-UCs showed this aberration. There was 100% concordance in the status of Her2 amplification between primary and progressive lesions. Immunohistochemistry and FISH results were in closest agreement when overexpression was defined as 50% of tumour cells showing immunoreactivity. The cumulative incidences of recurrence and progression in Her2-amplified HG-UC were significantly higher than in those without amplification. CONCLUSIONS: A subset of high-grade NMIBCs contain Her2 amplification and are associated with markedly aggressive behaviour. Her2 diagnostics are valuable for distinguishing patients who require diligent surveillance and would potentially benefit from anti-Her2 therapies.
Authors: Francesca Sanguedolce; Antonella Cormio; Paolo Massenio; Maria C Pedicillo; Simona Cagiano; Francesca Fortunato; Beppe Calò; Giuseppe Di Fino; Giuseppe Carrieri; Pantaleo Bufo; Luigi Cormio Journal: J Cancer Res Clin Oncol Date: 2018-01-23 Impact factor: 4.553
Authors: Johannes Breyer; Ralph M Wirtz; Mark Laible; Kornelia Schlombs; Philipp Erben; Maximilian Christian Kriegmair; Robert Stoehr; Sebastian Eidt; Stefan Denzinger; Maximilian Burger; Arndt Hartmann; Wolfgang Otto Journal: Virchows Arch Date: 2016-08-11 Impact factor: 4.064
Authors: Enrique Redondo-Gonzalez; Leandro Nunes de Castro; Jesús Moreno-Sierra; María Luisa Maestro de las Casas; Vicente Vera-Gonzalez; Daniel Gomes Ferrari; Juan Manuel Corchado Journal: Biomed Res Int Date: 2015-03-19 Impact factor: 3.411